Genovis AB (publ.) (GENO.ST)
SEK 19.58
(0.93%)
SEK 19.58
(0.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 98.04 Million SEK | 294.27% |
| 2022 | 24.86 Million SEK | -10.41% |
| 2021 | 27.75 Million SEK | 42.47% |
| 2020 | 19.48 Million SEK | 45.14% |
| 2019 | 13.42 Million SEK | 14.18% |
| 2018 | 11.75 Million SEK | 44.8% |
| 2017 | 8.11 Million SEK | 28.74% |
| 2016 | 6.3 Million SEK | -22.07% |
| 2015 | 8.09 Million SEK | 62.52% |
| 2014 | 4.97 Million SEK | -40.46% |
| 2013 | 8.36 Million SEK | 84.81% |
| 2012 | 4.52 Million SEK | 31.88% |
| 2011 | 3.43 Million SEK | 32.7% |
| 2010 | 2.58 Million SEK | -33.73% |
| 2009 | 3.9 Million SEK | -53.23% |
| 2008 | 8.34 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 95.8 Million SEK | -2.38% |
| 2024 Q1 | 98.14 Million SEK | 0.09% |
| 2023 Q2 | 24.24 Million SEK | -8.07% |
| 2023 Q1 | 26.37 Million SEK | 6.05% |
| 2023 Q3 | 101.83 Million SEK | 319.99% |
| 2023 FY | 98.04 Million SEK | 294.27% |
| 2023 Q4 | 98.04 Million SEK | -3.72% |
| 2022 Q3 | 24.51 Million SEK | 14.39% |
| 2022 FY | 24.86 Million SEK | -10.41% |
| 2022 Q1 | 19.98 Million SEK | -28.0% |
| 2022 Q2 | 21.43 Million SEK | 7.25% |
| 2022 Q4 | 24.86 Million SEK | 1.43% |
| 2021 Q3 | 15.54 Million SEK | -7.8% |
| 2021 Q4 | 27.75 Million SEK | 78.53% |
| 2021 Q2 | 16.86 Million SEK | -12.0% |
| 2021 FY | 27.75 Million SEK | 42.47% |
| 2021 Q1 | 19.16 Million SEK | -1.65% |
| 2020 Q2 | 18.69 Million SEK | 56.44% |
| 2020 FY | 19.48 Million SEK | 45.14% |
| 2020 Q3 | 17.3 Million SEK | -7.39% |
| 2020 Q4 | 19.48 Million SEK | 12.56% |
| 2020 Q1 | 11.94 Million SEK | -11.0% |
| 2019 Q3 | 18.09 Million SEK | 31.61% |
| 2019 Q4 | 13.42 Million SEK | -25.82% |
| 2019 Q2 | 13.75 Million SEK | 15.32% |
| 2019 FY | 13.42 Million SEK | 14.18% |
| 2019 Q1 | 11.92 Million SEK | 1.42% |
| 2018 Q4 | 11.75 Million SEK | -18.46% |
| 2018 Q2 | 18.22 Million SEK | 32.25% |
| 2018 Q1 | 13.78 Million SEK | 69.74% |
| 2018 FY | 11.75 Million SEK | 44.8% |
| 2018 Q3 | 14.41 Million SEK | -20.89% |
| 2017 FY | 8.11 Million SEK | 28.74% |
| 2017 Q4 | 8.11 Million SEK | 46.87% |
| 2017 Q2 | 5.26 Million SEK | -19.33% |
| 2017 Q1 | 6.52 Million SEK | 3.44% |
| 2017 Q3 | 5.52 Million SEK | 5.06% |
| 2016 Q4 | 6.3 Million SEK | 20.63% |
| 2016 FY | 6.3 Million SEK | -22.07% |
| 2016 Q2 | 7.25 Million SEK | -55.46% |
| 2016 Q3 | 5.22 Million SEK | -27.96% |
| 2016 Q1 | 16.29 Million SEK | 101.33% |
| 2015 Q3 | 5.89 Million SEK | -12.25% |
| 2015 Q1 | 6.93 Million SEK | 39.22% |
| 2015 Q2 | 6.72 Million SEK | -3.06% |
| 2015 FY | 8.09 Million SEK | 62.52% |
| 2015 Q4 | 8.09 Million SEK | 37.23% |
| 2014 Q1 | 5.23 Million SEK | -37.42% |
| 2014 Q3 | 5.34 Million SEK | -4.72% |
| 2014 Q4 | 4.97 Million SEK | -6.86% |
| 2014 FY | 4.97 Million SEK | -40.46% |
| 2014 Q2 | 5.61 Million SEK | 7.2% |
| 2013 Q4 | 8.36 Million SEK | 120.02% |
| 2013 Q2 | 4.81 Million SEK | 28.58% |
| 2013 Q1 | 3.74 Million SEK | -17.33% |
| 2013 FY | 8.36 Million SEK | 84.81% |
| 2013 Q3 | 3.8 Million SEK | -20.98% |
| 2012 FY | 4.52 Million SEK | 31.88% |
| 2012 Q2 | 4.46 Million SEK | 2.88% |
| 2012 Q3 | 3.83 Million SEK | -14.06% |
| 2012 Q4 | 4.52 Million SEK | 17.94% |
| 2012 Q1 | 4.34 Million SEK | 26.48% |
| 2011 Q1 | 2.87 Million SEK | 11.22% |
| 2011 Q4 | 3.43 Million SEK | 36.98% |
| 2011 FY | 3.43 Million SEK | 32.7% |
| 2011 Q3 | 2.5 Million SEK | -15.71% |
| 2011 Q2 | 2.97 Million SEK | 3.34% |
| 2010 Q2 | 4.32 Million SEK | -28.98% |
| 2010 Q4 | 2.58 Million SEK | 17.33% |
| 2010 Q3 | 2.2 Million SEK | -49.06% |
| 2010 Q1 | 6.09 Million SEK | 56.15% |
| 2010 FY | 2.58 Million SEK | -33.73% |
| 2009 Q4 | 3.9 Million SEK | 0.0% |
| 2009 Q1 | 4.43 Million SEK | 0.0% |
| 2009 FY | 3.9 Million SEK | -53.23% |
| 2008 FY | 8.34 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -950.766% |
| Amniotics AB (publ) | 10.54 Million SEK | -829.62% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -2115.251% |
| BioArctic AB (publ) | 139.5 Million SEK | 29.717% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 93.738% |
| Saniona AB (publ) | 86.08 Million SEK | -13.898% |
| Simris Alg AB (publ) | 148.93 Million SEK | 34.169% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -139.964% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -2454.638% |
| NextCell Pharma AB | 13.68 Million SEK | -616.244% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -611.952% |
| AcouSort AB (publ) | 10.37 Million SEK | -844.758% |
| Active Biotech AB (publ) | 13.4 Million SEK | -631.694% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 8.019% |
| Camurus AB (publ) | 414.81 Million SEK | 76.364% |
| Cantargia AB (publ) | 54.97 Million SEK | -78.365% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -430.156% |
| Mendus AB (publ) | 51.22 Million SEK | -91.405% |
| Kancera AB (publ) | 17.97 Million SEK | -445.372% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -747.498% |
| LIDDS AB (publ) | 3.75 Million SEK | -2510.41% |
| Lipum AB (publ) | 7.53 Million SEK | -1200.703% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1800.872% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 20.916% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -4056.295% |
| OncoZenge AB (publ) | 1.69 Million SEK | -5670.865% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 79.666% |
| Xintela AB (publ) | 14.01 Million SEK | -599.586% |
| Ziccum AB (publ) | 6.38 Million SEK | -1434.862% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -411.621% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -36.461% |
| CombiGene AB (publ) | 4.15 Million SEK | -2259.168% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -37.865% |
| Intervacc AB (publ) | 21.68 Million SEK | -352.246% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -183.348% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -267.107% |
| Corline Biomedical AB | 6.78 Million SEK | -1344.204% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -59.798% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -508.345% |
| Aptahem AB (publ) | 8.99 Million SEK | -989.674% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -112.315% |
| Fluicell AB (publ) | 8.91 Million SEK | -999.798% |
| Biovica International AB (publ) | 34.76 Million SEK | -182.012% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -740.307% |
| Abliva AB (publ) | 16.78 Million SEK | -484.274% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 54.312% |
| 2cureX AB (publ) | 2.93 Million SEK | -3240.613% |
| I-Tech AB | 16.2 Million SEK | -505.042% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 91.732% |
| Cyxone AB (publ) | 4.69 Million SEK | -1988.773% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -635.647% |
| Biosergen AB | 5.08 Million SEK | -1828.161% |
| Nanologica AB (publ) | 79.32 Million SEK | -23.599% |
| SynAct Pharma AB | 51.83 Million SEK | -89.156% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -1133.451% |
| BioInvent International AB (publ) | 90.45 Million SEK | -8.396% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1787.355% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 46.009% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -5365.273% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -669.358% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1250.51% |